The Cannabis Investing Podcast
The Cannabis Investing Podcast from Seeking Alpha is hosted by Rena Sherbill and focuses on actionable investment insight into the cannabis and psychedelics industries. The show provides context for understanding these emerging sectors through conversations with sector experts, top analysts, and C-level executives. Episodes highlight industry trends, share portfolio strategies, and help listeners think through their investing approach. Transcripts are available at seekingalpha.com/cannabisinvestingpodcast.
Episodes
'Let's go all in on cannabis' Grown Rogue's Obie Strickler & Josh Rosen
CEO and founder of Grown Rogue (GRUSF), Obie Strickler and Chief Strategy Officer, Josh Rosen discuss their paths in cannabis and why operations matter more than scale (1:00) (metrics that matter most (12:30) Uplisting and public vs private (20:40) What should retail investors be paying attention to? (24:40) On the price of cannabis (34:40)Show Notes:Grown Rogue Is Focused On Jersey, Yield, Cost A
Cannabis investing in the Trump era
Josh Rosen and Jerry Derevyanny from Bengal Capital discuss the current state of cannabis investing (1:10). Trump takes action to reschedule cannabis; federal regulations and investment strategies (6:30). Challenges of valuation in the cannabis sector (19:00). Expected consolidation in the industry; insights for retail investors (23:20). Is there a first mover advantage? (26:30). Understanding 280
Have cannabis investors been early or wrong or both?
Cannabis expert Jesse Redmond shares why he's now at LEEF Brands (1:30). Excited about New York's evolution (8:15). How and why it got so bad in the industry (16:00). Are we early or are we wrong? (22:05) Who may survive and get to the finish line (28:35). Intoxicating hemp market (32:40).Episode transcriptsShow Notes:Cannabis REITs: Less Risky Choices In A Risky SectorGreen Thumb Stands Alone. Bi
Cannabis REITs: less risky choices in a risky sector
Julian Lin updates his views on cannabis REITs IIPR and NewLake Capital (1:15). RIP Cannabis Growth Investor - changed thesis on cannabis MSOs (6:45). Why Green Thumb has done well relative to the sector (13:35).Episode transcriptsShow Notes:NewLake Capital: 9.3% Dividend Yield, No Net Debt, Rescheduling CatalystMarijuana rescheduling "delayed, but not dead": reportBest Of Breed Growth StocksFor f
High Tide CEO Raj Grover on Germany, Canada and the U.S.
High Tide is the largest cannabis retailer in Canada (1:20). President and CEO Raj Grover joins us to discuss its recent move into Germany (3:15). Purecan acquisition - a beautiful business to buy (8:00). Tilray is complementary, not competition (14:00). No hurry to get into the US (18:00). Contextualizing valuation and revisions (20:35).Read episode transcriptsShow Notes:High Tide outlines 2025 p
Green Thumb stands alone. Billions in debt coming for MSOs.
Why 2025 will be interesting and perhaps painful for the cannabis industry, according to Seth Yakatan (2:00). Enormous looming debt for many companies (5:15). GTI the only company consistently delivering year-in and year-out (8:30). TerrAscend, Ascend and the 2nd tier of MSOs (12:00). Glass House seemingly winning its bet on scalability (19:15). Which private companies have some of the best assets
Cause for concern in cannabis with a few rays of light
CannaVestments and Jerry Derevyanny return for an in-depth episode. Dissecting doom and gloom Q3 earnings for the cannabis industry (0:50). Green Thumb's consistently outstanding performance (4:25). Is it too early or too late to invest in cannabis? (11:15) Florida not legalizing - how much does it matter? (17:30) Agrify's interesting moves (35:40). Hemp, beverages and what may be worthy of invest
Grown Rogue is focused on Jersey, yield, cost and culture
Grown Rogue has been lauded by a number of analysts on this show so we decided to talk to VP Jake Iotte about what makes the company stand out and whether cannabis belongs in the CPG industry (1:30). Margins and ROI profile; focused on cash on cash returns (4:20). Excited about Jersey (7:10). Terminating partnership with Vireo (8:25). Not relying on federal legalization as a strategy (10:50).Read
Why cannabis is still an excellent long-term investment opportunity
Jesse Redmond highlights the fine line between being early and wrong and why having a long-term timeline is wise for cannabis investors (2:10). Why Florida is a massive opportunity (9:35). Green Thumb, Verano and pushing for more company transparency (17:50). Pennsylvania a state-led catalyst; solving for the current risks to getting into cannabis (26:05). Farm Bill flower, the hemp conversation,
Ayr CEO David Goubert on Florida, Ohio and 'very balanced' Q2
Ayr Wellness CEO David Goubert talks 'very balanced' Q2 earnings. (1:15) Focus on state footprints: Florida legalization, Ohio's nice rollout. (6:00) Debt and dilution: progress and strategies. (8:15) Any plans to grow hemp? (21:15) Industry valuations as the market evolves and legalization develops. (23:00) How to establish a national brand and the general cannabis retail picture. (36:00)Read epi
Psychedelic stocks: focus on their cash
Jason Najum has covered the psychedelic space for a long time and contextualizes recent news around the FDA, MDMA, PTSD and Lykos Therapeutics (1:35). Blessing in disguise for Cybin, COMPASS Pathways and MindMed (14:30)? Trial data and cash in the bank are top signifiers of success (22:35). How Atai fell behind and dropped out of the conversation (24:00). Upcoming catalysts - patience required (26
Cannabis investing in the age of legalization with Julian Lin, Tim Seymour and Pablo Zuanic
On June 18 at our Seeking Alpha Investing Summit, Pablo Zuanic, Tim Seymour, and Julian Lin discussed how to best invest in the sector (0:20). Best metrics to use when evaluating cannabis stocks (4:40). At this point in time, what is the best way to get into the sector? (19:00) Rescheduling, the Trump factor, investing in an election year (26:40). Originally published here with video.Cannabis Grow
Cannabis investing masterclass with Julian Lin + Jerry Derevyanny
Jerry Derevyanny and Julian Lin break down the current state of the cannabis sector (1:00). How companies are massaging their earnings results (3:30). Proper metrics to use as the market develops (7:45). Green Thumb's growth mode and solid margins (16:05). Institutional capital and what will really make the industry soar (21:15). Thoughts on Verano and Goodness Growth (47:25). New states coming on
Looking for the Bud Light of cannabis
Alex Carchidi talks why he's bullish on the cannabis sector, but not ready to buy stocks (1:15) except for IIPR (2:15). 2 cannabis stocks worth looking at (7:25). Tilray the only international option (13:30). Who looks good in Canada (16:40). Why Alex avoids MSOS ETF (22:30). Legalization, rescheduling and incremental change (23:20).Show Notes:Biden administration reportedly moves to reclassify ma
What has Verano so optimistic about the cannabis industry?
Verano (VRNOF) CEO George Archos and CIO Aaron Miles on recent earnings and why they're the most optimistic they've been (0:45). Company transparency like state by state data (7:50) and what metrics they're each focused on (12:05). Why they're so excited about Florida, Ohio and Pennsylvania (14:35). The federal regulation roller coaster (21:05).Show Notes:How Retail Investors Should Evaluate Canna
Mario Naric on Canada's shakeout phase
Mario Naric, CEO and Founder of Motif Labs, discusses being in the shakeout phase of cannabis in Canada (1:00). Staying private while public companies suffer (5:25). How to grow market share in Canada (12:53). Near-term reality for big Canadian LPs like Tilray and Canopy Growth (18:00). Different products for different markets within US and Canada (23:20). Where should investors allocate their cap
Cannabist CEO David Hart on breathtaking volatility and technical overhangs
David Hart recently became CEO of The Cannabist Company and is focused on building a strong asset base in the US cannabis market (1:35). Metrics and internal expectations, wholesale business; finding ways to improve margin profile and cash generation (11:25). Is more transparency coming?(14:45) Thoughtful ways of approaching debt (17:10). Industry rallies, price drops and technical overhangs (26:4
How retail investors should evaluate cannabis stocks
Bengal Capital's Jerry Derevyanny shares his evolving thoughts on 280E and the process of rescheduling cannabis (2:20). Some uncomfortable truths about how investors should be evaluating cannabis stocks (8:30). When will companies become more transparent? (21:40) Who is handling debt well and who isn't (27:15). Examples of sustainable value creation in the industry (34:00).Episode transcriptsShow
An unvarnished look at New York + California cannabis markets
Katie Neer and Hirsh Jain break down the dispiriting New York and California cannabis markets (3:00). What the 2 states have gotten wrong, and why it's not being corrected (9:55). Dysfunction and pushing regulators and the law to work better (34:45). Are there investment opportunities in either market? (47:40)Episode transcriptsShow Notes:Unpacking New York And California Cannabis MarketsWhat's Th
Alan Brochstein on rescheduling overexcitement, MSOs, Canada and the burden of 280E
Alan Brochstein thinks investors are overly excited about the recent rescheduling announcement, which he says is really no news at all (2:20) Balance sheets, debt, income tax payable and the burden of 280E (4:00) California and New York continuing challenges (23:20) What's right and wrong with Canada (32:30) Broad and specific thoughts on MSOs (38:10).Subscribe to Alan's 420 InvestorEpisode transc
De-risking psychedelics: Compass Pathways, Cybin and Atai
Alex Carchidi updates us on the psychedelic sector and what critical catalysts are approaching (1:30). Why Compass Pathways, Cybin, and Atai make the most sense for investors at this point (15:00). Pros and cons of 4 main industry stocks, including MindMed (29:50).Episode transcriptsShow Notes:Psychedelic Stocks = Super-Risky Biotechs Low On Cash. Make Small Bets.Psychedelic Stocks: Don't Bet On J
Investing In cannabis? Stay patient, be ready
A rundown of reasons to be hopeful and some compelling advice from some of our favorite 2023 conversations. Why Chris DeMuth likes the opportunity in cannabis (1:20) Julian Lin on M&A, debt and disappointment (10:05) Alan Brochstein: waiting for catalysts while working through tough times (12:20) Jesse Redmond discusses the best way to invest in this space (13:35) Emily Paxhia on SG&A cont
Cannabis investors - what you should know
Nick Gastevich, aka CannaVestments, talks Q3 cannabis efforts; avoiding dilution, equity raises or adding further debt (2:30). Navigating the industry as a retail investor; companies that protect shareholders (14:00). The future of 280E, catalysts definitely needed (24:00). 7 stocks - what's working, what's not (30:00).Show Notes:What Cannabis Stocks Should Be In Your Portfolio?Searching For Canna
TerrAscend's Jason Wild: Not all EBITDA numbers are created equally
TerrAscend's Executive Chairman Jason Wild returns. Focused on not spreading itself too thin ("we'd rather be more focused, spend more money, get more scale, like we did in Jersey") and why not all EBITDA numbers are created equally (8:50). Should cannabis companies pay their taxes? (11:40) Pushing for real legislative change with famed lawyer David Boies (13:30).Show Notes:TerrAscend GAAP EPS of
Cannabis ETF deep dive
Do ETFs make sense for everyone? ETF expert Rob Isbitts discusses his thesis on cannabis ETFs and the importance of understanding their structure and holdings (8:00). The need for a diversified but not overly diversified portfolio and the importance of technical analysis in evaluating ETFs (24:50).Show Links:MSOS: An Industry-Wide Catalyst ApproachesA Close Look At 13 Cannabis ETFsDefying The Odds
Chris DeMuth talks cannabis, SAFE banking + SHF Holdings
Chris DeMuth talks about investing in the cannabis industry (1:30) legalization, SAFE banking and whether the investment community cares (9:00) and why he's so bullish on SHF Holdings (14:45).Subscribe to Chris' Sifting The World Transcript on Seeking AlphaShow NotesSifting The World Day OneSPAC Week II: Cannabis SPACsA Close Look At 13 Cannabis ETFsFor full access to analyst ratings, stock quant
Is it really time to be bullish on cannabis stocks?
Jesse Redmond returns to discuss why it's ok to be bullish on the cannabis industry (4:30) political catalysts, 280E and excise taxes (12:15) picking companies based on your investing horizon (15:00) Green Thumb's dominance and lack of transparency (20:55) AYR's debt strategy (23:10) Trulieve's tough period (21:00) California players (38:00) and TerrAscend's innovation and execution (44:55).Transc
Cannabis stocks have been rallying but when will capital flow into the industry?
Emily Paxhia discusses recent positive news for the industry and its accompanying rally (2:00), the long-term play in cannabis, especially for retail investors (6:10), Green Thumb's share repurchase and can any other operator keep up? (13:40) TerrAscend's smart TSX move (16:10) New York, California, Glass House scale, private companies and the Gold Flora deal (18:20) and looking at the right metri
Cannabis investing with Alan Brochstein & Julian Lin - REITs + Canadian LPs over MSOs
Alan Brochstein and Julian Lin discuss investing in cannabis stocks and mistakes made along the way (3:00). Why companies should be more aggressive in paying down debt (9:00) Investing timelines and federal legalization (19:00) Cannabis REITs and Canadian LPs over MSOs (23:45). Subscribe to Julian's Cannabis Growth InvestorSubscribe to Alan's 420 InvestorShow Notes:Innovative Industrial: Top Canna
Virtual reality + psychedelic therapy
Enosis Therapeutics combines virtual reality with psychedelic psychotherapy protocols. Founders Dr. Prashanth Puspanathan and Agnieszka Sekula discuss why VR makes sense for psychedelic therapy and where capital should really be allocated to in the space.Episode transcripts can be found on Seeking AlphaFor full access to analyst ratings, stock quant scores and dividend grades, subscribe to Seeking
Texas cannabis, delta-8 and delta-9 with Paul Trowe
Paul Trowe talks about going from crypto to cannabis by founding Herban Bud in Austin, Texas (5:00). Breaking down cannabinoids and legal loopholes: THC, THCA, Delta 8 and Delta 9 (9:25) Texas, cannabis legalization and educating law enforcement and government (14:15). Maintaining integrity in a shady lane of the industry (27:00) Paul's thoughts on Bitcoin and Ethereum and why he's not currently i
Psychedelic stocks = super-risky biotechs low on cash. Make small bets.
Analyst Alex Carchidi returns to update investors on the psychedelics industry. This is the full conversation of an interview originally published on Investing Experts.(2:50) Industry's collapse and consolidation(5:00) Compass Pathways timeline for clinical trials(15:00) Super-risky biotech companies low on cash - don't bet on just 1 company(21:20) Atai and Cybin's recent wins(32:55) Ketamine clin
Psychedelics gaining acceptance; what does it mean for investors?
Derek Du Chesne and Dr. Sam Zand founded Better U and today discuss getting into ketamine therapy (4:00), psychedelics gaining more legal and medical acceptance (23:00), industry differences between cannabis and psychedelics (27:30) and advice for investing in the space (42:30).Cannabinoid Consolidation (Derek's previous appearance)Numinus CEO Payton Nyquvest On Transforming Healthcare With Psyche
MariMed CEO Jon Levine: Cannabis industry still missing the real investments
MariMed (MRMD) CEO Jon Levine discusses steady growth and the cannabis retail market.(8:30) - Owning real estate and consecutive quarters of positive cash flow(12:10) - Maryland, Missouri excitement(17:45) - Raising money at relatively decent rates(27:30) - Legalization, interstate commerce and future growthOrganic Growth With MariMedWho Can Survive In Cannabis?What Cannabis Stocks Should Be In Yo
Cultivating profitable cannabis
(3:00) - Headwaters' Nick Brandis on one of the largest cannabis cultivators you've never heard of(8:00) - Why greenhouses will be the winning method in the long run(13:15) - Deciphering cannabis pricing volatility and compression(40:15) - Partnering with Glass House (GLASF), competition and the illicit marketOur links:The Cannabis Investing PodcastThe Cannabis Investing Podcast provides actionabl
Not necessarily time to buy cannabis stocks - Alan Brochstein
Alan Brochstein is back to share his cannabis investing insights.(2:50) - 420 Investor's origin story(8:30) - Cannabis investing timeline - now is not necessarily the time to buy cannabis stocks(17:50) - Ayr's (AYRWF) debt and executive changes(24:00) - Tangible book value and how to gauge cannabis stocks(29:00) - Planet 13 (PLNHF) a business that's managed well(34:40) - Still bullish on WM Techno
4Front Ventures: Cash flow break-even probably the only KPI that matters
4Front Ventures' (FFNTF) Brandon Mills joins us to discuss how they're making it work in an incredibly challenging environment. In California, not being vertically integrated, or even partially vertically integrated is a business model that's really tough to sustain (5:00), addressing the multitude of headwinds (11:40), cultivation, gross margins and Glass House (GLASF) (15:00), Illinois growth op
What will catalyze psychedelic stocks?
Psychedelics are being pulled into the mainstream by medical research (9:00). Filament Health CEO Benjamin Lightburn on Psilocybin and why of all the psychedelics it probably lends itself best to a recreational market (15:00). Microdosing clinical trials (19:00) real revenue generation (28:00) and challenges around psychedelic patents (33:30).Our links:The Cannabis Investing PodcastThe Cannabis In
Tremendous opportunity in cannabis
Outlining the cannabis industry's Haves (companies that have been able to raise capital) and The Have Nots (no ability to raise capital) with Seth Yakatan. The keys to making a deal and raising capital (9:10), Why Seth prefers real EBITDA and revenue to book value (14:00), Glass House, 4Front; California's created tremendous opportunity (24:50), better to be private than public? (38:00) legal and
Ayr Wellness CEO David Goubert Focused On Debt And Cash
David Goubert, recently minted CEO and President of Ayr Wellness (AYRWF), discuses coming on board (3:00), working through debt, strategizing for positive free cash flow (19:00), pricing, margins and inventory (25:30), integrating acquisitions; updates on Florida and Nevada (33:00).Our links:The Cannabis Investing PodcastThe Cannabis Investing Podcast provides actionable investment insight and the
Unpacking New York And California Cannabis Markets
Hirsh Jain joins Jeffrey Schultz to break down what's happening - and what's not - in the New York and California cannabis markets. Updates on New York's legal rollout (5:20), California (13:40), decriminalization without regulation (16:00), pushing for interstate commerce (29:40) and the future of the industry for public companies (50:00).Our links:The Cannabis Investing PodcastThe Cannabis Inves
Imran Khan On Psychedelics - More We Don't Know Than We Do
Imran Khan is Executive Director of the Berkeley Center for the Science of Psychedelics. With psychedelics, there's more that we don't know than we do (3:00) Science behind microdosing - it's too early to tell (5:15) Psychedelic placebo challenges (8:00) What would the ideal psychedelic space look like? (17:50) Retail side of psychedelics (24:45) Catalysts and risks (27:30)Our links:The Cannabis I
Where Is The Value In Cannabis Stocks?
Where Jerry Derevyanny, a partner at Bengal Capital, believes we can find the most value from cannabis stocks. (3:35) Why EBITDA falls short as a useful metric for cannabis investors. (8:15) Moving away from the top multi-state operators (MSOs). (16:20) REITs, problematic business models and risks around rent payment. (22:40) AYR, Goodness Growth and more (30:00).Our links:The Cannabis Investing P
Cannabis Is A Psychedelic - Dr. Julie Holland
Dr. Julie Holland is a psychiatrist/psychopharmacologist, author, medical advisor to MAPS, and a medical monitor for several clinical studies. (3:30) - Why cannabis is a psychedelic(6:00) - Involvement with MAPS; drugs and medicine(11:00) - The biggest risk in psychedelic treatment(14:30) - Placebos and psychedelics(23:00) - Investing in the space, advising psychedelic VC fund(29:00) - Psychedelic
Ascend's Attractive Assets
Ascend (AAWH) has been one of the MSOs that analysts have been writing about on Seeking Alpha and championing on this podcast recently. CFO and interim co-CEO Dan Neville joins us to discuss looking for new leadership and what investors should be focused on in the space.(3:10) - The search for Ascend's new CEO(11:35) - MSO 2.0 strategy(16:40) - Ascend's East Coast assets(22:00) - U.S. adult-use ba
Pragmatic Cannabis Investing
Rob Sechrist discusses starting Pelorus Equity Group and its Fund, a privately held mortgage real estate investment trust (mREIT) (2:39) Capital crunch in the cannabis industry ('the income is there; where the difficulty is is deriving net profit from that gross revenue') (6:20) Private operators in California seeing success (10:20) Advice to retail investors (12:50) Investing style and strategy w
Numinus CEO Payton Nyquvest On Transforming Healthcare With Psychedelics
Mental health is perhaps the biggest health issue facing society and traditional medicine has been limited in its success treating it. Psychedelic compounds have been healing people for thousands of years but there are challenges around how to properly service the public. Numinus CEO Payton Nyquvest discusses focusing on profitability and the need for service providers to be able to offer various
Cannabis Investing Podcast Roundtable
The first ever cannabis investing podcast roundtable discussion with Bryan Fields + Kellan Finney, Benzinga's Javier Hasse and Patrick Aylward. Investing in the cannabis industry: stocks, ETFs and patience (and be honest about risk!). Mistaken assumptions around illicit to legal markets. Confronting synthetic cannabinoids. Excitement over young markets like Oklahoma while bigger markets like New Y
Organigram CEO Beena Goldenberg - Expanding Beyond Canada
Organigram (OGI) CEO Beena Goldenberg talks the changing (and challenging) Canadian cannabis market. Balance sheet strength and British American Tobacco's significant investment. Looking towards the US and beyond. The importance of regulators helping educate consumers.Our links:The Cannabis Investing Podcast: https://seekingalpha.com/cannabisinvestingpodcastOn The Cannabis Investing Podcast, host
Looking For The Cheapest Cannabis Stocks
Cannabis stocks are really cheap, but Alan Brochstein is worried about 3 things. We discuss sector debt and optimal cannabis investing metrics; Canadian and US operators; concerns around MSOS, limitations of ETFs. Thoughts on the Cresco/Columbia Care deal. Why Alan's 19% in cash.Our links:The Cannabis Investing Podcast: https://seekingalpha.com/cannabisinvestingpodcastOn The Cannabis Investing Pod
Psychedelic Sunday: Mushrooms Are The Key - Red Light Holland CEO Todd Shapiro
Red Light Holland CEO Todd Shapiro talks recreational approach to psilocybin and its focus on near-term revenue - a rarity in the psychedelic space. Growing different kinds of mushrooms. Loyal retail investors essential to growth. Recent auditor change. Partnering with Wiz Khalifa, Russell Peters as CCO; path to legalization and profitability. Look at psychedelic companies' run rates.Our links:The
Wana Brands CEO Nancy Whiteman On Growth With Conviction
Wana Brands CEO Nancy Whiteman on being one of the top edible brands in North America and how they grew without outside capital - never take money you don't need. Getting acquired by Canopy Growth, differences between the Canadian and US cannabis markets. Delta 8 and concerns around synthetically derived hemp.Our links:The Cannabis Investing Podcast: https://seekingalpha.com/cannabisinvestingpodca
What Cannabis Stocks Should Be In Your Portfolio?
Nick Gastevich, aka CannaVestments, one of our favorite commenters on Seeking Alpha, returns for a super actionable take on cannabis stocks. Focus on companies that control their own destinies as much as possible. Which balance sheets are in trouble and who's generating real cash flow. Diving deep into the top multi-state operators + AYR (AYRWF), MariMed (MRMD), C21 Investments (CXXIF), California
Psychedelic Sunday: Ketamine Assisted Therapy
When will capital markets catch up to the psychedelic industry? Ronan Levy, CEO and Co-Founder of Field Trip, discusses strategy behind focusing on ketamine assisted therapy and why splitting up Reunion Neuroscience (REUN) (drug development) and Field Trip (FTHWF) (clinical infrastructure) made the most sense ('The FDA likes things in neat tidy boxes'). Adult-use psychedelic market has already beg
Depressed Valuations, Consolidation Coming
How should cannabis investors ride the wave of depressed valuations? Tiby Erdely, who came to cannabis from Goldman Sachs and co-founded KEY Investment Partners, talks about why consolidation is coming. We also discuss why investors should get deep into companies' income statements and balance sheets and focus primarily on the last 6-12 months of performance. Why the top 5 multi-state operators (T
Cannabis Is A Commodity
As the industry develops, lots of talk recently around cannabis consumption lounges and cannabis tourism in Colorado, Nevada and beyond. What it's like to grow the cannabis economy with Chris Chiari, CEO/Founder of The 420 Hotels. Cannabis is a commodity - what that means for pricing and business models.Our links:The Cannabis Investing Podcast: https://seekingalpha.com/cannabisinvestingpodcastOn T
Psychedelic Sunday: Competitive Strategies
Stephen Tobin on investing in psychedelic stocks while they're still pre-revenue. Why he's a big believer in Compass Pathways (CMPS) and Atai Life Sciences (ATAI) and not as much in Cybin (CYBN) or MindMed (MNMD). Will first-movers get the advantage? What will move share prices? The importance of patents and cash in the industry.
What's The Deal With New York Cannabis?
Legal cannabis has officially hit New York. Two long-time advocates, Allan Gandelman and Kaelan Castetter, came on when New York first went legal and return to provide context for this moment. We discuss when supply might meet demand, why the two-tier system works and will likely be a federal model, the illicit market, and the obscene value of NY licenses.
Psychedelic Sunday: Scrutinizing Psychedelic Stocks
What makes a psychedelic company compelling? Analyst Alex Carchidi has a background in biotech and focuses on long-term growth and risk management. He shares what investors should focus on in the psychedelic space and the pros and cons of owning his top 5 psychedelic stocks.
Cannabis Is A Long-Term Play
Negative conditions are crashing down all around investors. Make sure companies in your portfolio will survive. Ted Waller shares why some stocks are falling off a cliff. Not all ETFs are created equal - stay away from the leveraged ETFs ('dynamite ready to be lit'). Pinning hopes on current cannabis leaders. Cash flow is extremely important.
MasterClass In Cannabis Investing Redux
James Baker and Julian Lin are two standout analysts who have joined us over the years for 3 MasterClasses in cannabis investing. This is a compilation of highlights from those shows. As the last episode of the year, and as we've been met with more political gridlock and disappointment, we would do well to remind ourselves of some investing truths, let go of outdated hopes and focus more on desche
Psychedelic Sunday: 4 Stock Overview
Welcome to the 2nd episode of Psychedelic Sunday, where we delve into psychedelics and investing. Today we give an overview of the 4 main stocks in psychedelics, focusing on recent earnings calls and analyst Q&A for Compass Pathways (CMPS), Atai Life Sciences (ATAI), MindMed (MNMD) and Cybin (CYBN). We'll be diving even deeper into these stocks over the next couple of weeks with the help of St
The Curious Cannabis Industry
Celebrating episode 200 with Emily Paxhia! Time to reset expectations and focus the conversation on rescheduling (or descheduling!) cannabis. Dysfunction at the federal level - not passing cannabis banking reform is in direct opposition to majority of US voters. Sidestepping the froth with the PSDN ETF. Small cap value story. Top companies already positioned for uplisting, but what are the rules o
Psychedelic Sunday!
Welcome to the first ever Psychedelic Sunday episode! There is a lot of overlap between cannabinoid and psychedelic experiences and today we launch our coverage of the psychedelics industry. Challenges and opportunities within psychedelics; highlighting four stocks: Compass Pathways (NASDAQ:CMPS), Cybin (NYSE:CYBN), Atai Life Sciences (NASDAQ:ATAI), and MindMed (NASDAQ:MNMD).
Who Can Survive In Cannabis?
How should you build your cannabis portfolio? Analyst Jesse Redmond shares his thoughts on MSOs, ETFs and smaller players. Green Thumb resignations, stepping away from Ascend. California, New Jersey and the obligatory SAFE discussion. His favorite strains and why he grows his own cannabis.Show Links:Jesse Redmond on Seeking AlphaFollow The Cannabis Investing PodcastSubscribe to Seeking Alpha Premi
Beware Canada 2.0
With tech stocks crashing, are cannabis stocks the most compelling investment right now? Julian Lin tells investors to focus on MSOs that can generate free cash flow right now. Price compression has been far more severe than expected. What rising interest rates means for the cannabis industry. Why Julian's so bullish on NewLake Capital.
Cannabis Industry Waiting On Change
Fairly disappointing news out of the US as only 2 of the 5 states that had adult-use cannabis on the ballots passed it. With Biden's recent promises amid a protracted regulatory process, will investors' and activists' frustration lead to change? What we as investors can look forward to in the industry.
Glass House's Graham Farrar On Industry Challenges And Opportunities
Glass House aims to be free cash flow positive. Co-Founder and President Graham Farrar comes back to discuss the opportunity and challenge in fighting its main competition - California's illicit market. We also discuss why he thinks Biden's recent announcements are more strategy than stunt and why Glass House won't be at MJBizCon.
Legalized States Driving Cannabis Growth
BDSA provides market research and data solutions for the cannabis industry. CEO Roy Bingham discusses state by state legalization, development of illicit market, lack of consequences. Why he's cautious about the international market.
Agrify's Pivot With CEO Raymond Chang
Agrify (AGFY) CEO Raymond Chang joined me last year on CEO Interviews to discuss the business model of indoor vertical farming. We recorded this interview before Agrify's recent stock split, but we do discuss the current challenging environment and the pivot the company is now focused on. Rapid deployment, the necessity for consistency, addressing industry pain points and growing segments.
Scaling Towards Legalization
Entourage Effect Capital Founder and StateHouse (STHZF) Chairman Matt Hawkins returns to discuss cautiously hunting for distressed assets, the transformative outlook of new regions going legal and developing legislation. Private equity, institutional capital wanting in on cannabis.
New York Cannabis - The Catalyst People Aren't Talking About
Weedmaps CEO Chris Beals joined me recently at Benzinga's Cannabis Capital Conference to discuss scaling a cannabis marketplace. The arduous task of policing the platform, whether brand loyalty really exists and the catalyst that people aren't talking about.
Verano: How To Succeed In U.S. Cannabis
Chief Investment Officer Aaron Miles shares why Verano (VRNOF) got dinged when it went public and how it's shaping its strategy as the market continues to develop. We discuss the Goodness Growth (GDNSF) acquisition, New York's protracted timeline and investing dollars at the right time. One of the top MSOs, find out why Seeking Alpha authors and Wall Street analysts rate Verano as a Strong Buy and
Tim Seymour On Constructive Pessimism In Cannabis
Live from Chicago's Benzinga Cannabis Capital Conference with Fast Money's Tim Seymour! Why MSOs are still the most interesting investments but some are separating from others. Tim's conversation with Boris Jordan. Oversupply in the market. People aren't as optimistic and why that's a good thing.
Lowell Farms' Focus on Flower: Pre-Rolled Cannabis
Cannabis flower usage and pre-rolls with Lowell Farms' Chairman George Allen. The developing retail picture, competitive form factors and the maturing consumer. Lowell's new 35s, bringing elegance to joints and making sense of the industry.
Cannabis In Germany - Legalize, Don't Decriminalize
Talking cannabis legalization in Germany with Niklas Kouparanis, CEO and Co-Founder of Bloomwell Group - one of Germany’s largest cannabis companies. We talk about legalizing the whole value chain. The mistake of decriminalizing before legalizing. Learning the lessons from already legal markets.
CPG And Cannabis - A Conversation With Troy Datcher
Coming from blue chip CPG companies like Clorox, Troy Datcher came on board as CEO for TPCO Holding (GRAMF) last year. Troy said that he's longed to have a relationship this intimate with the consumer in previous industries. "Candidly, I didn't own the experience." In cannabis TPCO reaches about 70% of California consumers. Creating a different company from how it started. Encouraged by legislativ
Cannabis Consumption
Spending more time on the California cannabis market with Lauren Fontein, one of the founders of The Artist Tree, a beautiful new consumption lounge in West Hollywood and Courtney Caron, an instrumental part of the developing retail picture in California. This week we sat on the lounge's balcony and discussed the baby steps happening in the cannabis industry, what retail consumption looks like, an
California's Cannabis Market - Deep Dive, Part II
Emily Paxhia and Hirsh Jain return to catch us up on the California cannabis market and beyond. Getting out of the death spiral but not quite out of the woods yet. Elimination of cultivation tax, but other taxes remain. Incremental progress, but is California moving in the right direction? What parts of the supply chain will benefit? Cannabis pricing, legal vs illicit. Moving towards commoditizati
Cannabis Micro/Macro Picture
Jon DeCourcey shares how his cannabis investing philosophy has shifted over the past few months. Micro vs macro perspective, risk on vs risk off environment. What is going on in Washington? Is there reason for more optimism on political front? Moving pieces of continued cannabis expansion and what's happening beyond companies' control.
